NCT00337103_2B: NCT00337103, figure 2B

NCT00337103_2BR Documentation

NCT00337103, figure 2B

Description

Kaplan-Meier digitized data from NCT00337103, figure 2B (PMID 25605862). A reported sample size of 1,102 for a primary endpoint of OS/PFS in breast cancer.

Usage

NCT00337103_2B

Format

A data frame of 1,102 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (cap, eribulin)

Source

Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33: 594–601.

Examples

summary(NCT00337103_2B)

kmplot(NCT00337103_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.